{"id":271,"date":"2018-08-31T01:04:59","date_gmt":"2018-08-31T01:04:59","guid":{"rendered":"https:\/\/nuwiq.wpengine.com\/hcp\/about-nuwiq\/human-cell-line\/"},"modified":"2025-01-09T17:47:01","modified_gmt":"2025-01-09T17:47:01","slug":"human-cell-line","status":"publish","type":"page","link":"https:\/\/nuwiqusa.com\/hcp\/about-nuwiq\/human-cell-line\/","title":{"rendered":"Human Cell Line"},"content":{"rendered":"\n<p>FVIII replacement therapy is the standard of care for Hemophilia A &ndash; trusted and proven to be safe and effective over decades of use<sup>1<\/sup>. However, not all FVIII treatments are the same. There are differences in the way they are manufactured, purified, and importantly, in the host cell line that is used for expression of the rFVIII protein.<\/p>\n<p>NUWIQ is the first and only rFVIII produced in a human cell line without chemical modification or protein fusion.<sup>2,3<\/sup>. In fact, no animal proteins are added during the production of <a href=\"https:\/\/nuwiqusa.com\/hcp\/about-nuwiq\/what-is-nuwiq\/\">NUWIQ<\/a>.<sup>4<\/sup><\/p>\n\n","protected":false},"excerpt":{"rendered":"<p>FVIII replacement therapy is the standard of care for Hemophilia A &ndash; trusted and proven to be safe and effective&#8230;<\/p>\n","protected":false},"author":23,"featured_media":0,"parent":422,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-271","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Human Cell Line FVIII Replacement Therapy - NUWIQ\u00ae\ufe0f Official HCP Website<\/title>\n<meta name=\"description\" content=\"NUWIQ\u00ae is the only rFVIII therapy produced in a human cell line without chemical modification or protein fusion, offering human glycosylation for stability and reduced immunogenicity. Learn more.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nuwiqusa.com\/hcp\/about-nuwiq\/human-cell-line\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Human Cell Line FVIII Replacement Therapy - NUWIQ\u00ae\ufe0f Official HCP Website\" \/>\n<meta property=\"og:description\" content=\"NUWIQ\u00ae is the only rFVIII therapy produced in a human cell line without chemical modification or protein fusion, offering human glycosylation for stability and reduced immunogenicity. Learn more.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nuwiqusa.com\/hcp\/about-nuwiq\/human-cell-line\/\" \/>\n<meta property=\"og:site_name\" content=\"NUWIQ\u00ae Healthcare Professionals\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-09T17:47:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nuwiqusa.com\/hcp\/wp-content\/uploads\/sites\/2\/2022\/05\/SocialShare_1200x630.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/about-nuwiq\\\/human-cell-line\\\/\",\"url\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/about-nuwiq\\\/human-cell-line\\\/\",\"name\":\"Human Cell Line FVIII Replacement Therapy - NUWIQ\u00ae\ufe0f Official HCP Website\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/#website\"},\"datePublished\":\"2018-08-31T01:04:59+00:00\",\"dateModified\":\"2025-01-09T17:47:01+00:00\",\"description\":\"NUWIQ\u00ae is the only rFVIII therapy produced in a human cell line without chemical modification or protein fusion, offering human glycosylation for stability and reduced immunogenicity. Learn more.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/about-nuwiq\\\/human-cell-line\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/about-nuwiq\\\/human-cell-line\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/about-nuwiq\\\/human-cell-line\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"About NUWIQ\",\"item\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/about-nuwiq\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Human Cell Line\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/#website\",\"url\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/\",\"name\":\"NUWIQ\u00ae Healthcare Professionals\",\"description\":\"[Antihemophilic Factor (Recombinant)]\",\"publisher\":{\"@id\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/#organization\",\"name\":\"NUWIQ\u00ae (Antihemophilic Factor [Recombinant])\",\"url\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2022\\\/05\\\/SocialShare_1200x630.jpg\",\"contentUrl\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2022\\\/05\\\/SocialShare_1200x630.jpg\",\"width\":1200,\"height\":630,\"caption\":\"NUWIQ\u00ae (Antihemophilic Factor [Recombinant])\"},\"image\":{\"@id\":\"https:\\\/\\\/nuwiqusa.com\\\/hcp\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Human Cell Line FVIII Replacement Therapy - NUWIQ\u00ae\ufe0f Official HCP Website","description":"NUWIQ\u00ae is the only rFVIII therapy produced in a human cell line without chemical modification or protein fusion, offering human glycosylation for stability and reduced immunogenicity. Learn more.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nuwiqusa.com\/hcp\/about-nuwiq\/human-cell-line\/","og_locale":"en_US","og_type":"article","og_title":"Human Cell Line FVIII Replacement Therapy - NUWIQ\u00ae\ufe0f Official HCP Website","og_description":"NUWIQ\u00ae is the only rFVIII therapy produced in a human cell line without chemical modification or protein fusion, offering human glycosylation for stability and reduced immunogenicity. Learn more.","og_url":"https:\/\/nuwiqusa.com\/hcp\/about-nuwiq\/human-cell-line\/","og_site_name":"NUWIQ\u00ae Healthcare Professionals","article_modified_time":"2025-01-09T17:47:01+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/nuwiqusa.com\/hcp\/wp-content\/uploads\/sites\/2\/2022\/05\/SocialShare_1200x630.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nuwiqusa.com\/hcp\/about-nuwiq\/human-cell-line\/","url":"https:\/\/nuwiqusa.com\/hcp\/about-nuwiq\/human-cell-line\/","name":"Human Cell Line FVIII Replacement Therapy - NUWIQ\u00ae\ufe0f Official HCP Website","isPartOf":{"@id":"https:\/\/nuwiqusa.com\/hcp\/#website"},"datePublished":"2018-08-31T01:04:59+00:00","dateModified":"2025-01-09T17:47:01+00:00","description":"NUWIQ\u00ae is the only rFVIII therapy produced in a human cell line without chemical modification or protein fusion, offering human glycosylation for stability and reduced immunogenicity. Learn more.","breadcrumb":{"@id":"https:\/\/nuwiqusa.com\/hcp\/about-nuwiq\/human-cell-line\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nuwiqusa.com\/hcp\/about-nuwiq\/human-cell-line\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nuwiqusa.com\/hcp\/about-nuwiq\/human-cell-line\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nuwiqusa.com\/hcp\/"},{"@type":"ListItem","position":2,"name":"About NUWIQ","item":"https:\/\/nuwiqusa.com\/hcp\/about-nuwiq\/"},{"@type":"ListItem","position":3,"name":"Human Cell Line"}]},{"@type":"WebSite","@id":"https:\/\/nuwiqusa.com\/hcp\/#website","url":"https:\/\/nuwiqusa.com\/hcp\/","name":"NUWIQ\u00ae Healthcare Professionals","description":"[Antihemophilic Factor (Recombinant)]","publisher":{"@id":"https:\/\/nuwiqusa.com\/hcp\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nuwiqusa.com\/hcp\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/nuwiqusa.com\/hcp\/#organization","name":"NUWIQ\u00ae (Antihemophilic Factor [Recombinant])","url":"https:\/\/nuwiqusa.com\/hcp\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/nuwiqusa.com\/hcp\/#\/schema\/logo\/image\/","url":"https:\/\/nuwiqusa.com\/hcp\/wp-content\/uploads\/sites\/2\/2022\/05\/SocialShare_1200x630.jpg","contentUrl":"https:\/\/nuwiqusa.com\/hcp\/wp-content\/uploads\/sites\/2\/2022\/05\/SocialShare_1200x630.jpg","width":1200,"height":630,"caption":"NUWIQ\u00ae (Antihemophilic Factor [Recombinant])"},"image":{"@id":"https:\/\/nuwiqusa.com\/hcp\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nuwiqusa.com\/hcp\/wp-json\/wp\/v2\/pages\/271","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nuwiqusa.com\/hcp\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/nuwiqusa.com\/hcp\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/nuwiqusa.com\/hcp\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/nuwiqusa.com\/hcp\/wp-json\/wp\/v2\/comments?post=271"}],"version-history":[{"count":0,"href":"https:\/\/nuwiqusa.com\/hcp\/wp-json\/wp\/v2\/pages\/271\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/nuwiqusa.com\/hcp\/wp-json\/wp\/v2\/pages\/422"}],"wp:attachment":[{"href":"https:\/\/nuwiqusa.com\/hcp\/wp-json\/wp\/v2\/media?parent=271"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}